{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:20:35Z","timestamp":1788427235391,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Clinical research participation among patients with prostate cancer remains limited, and demographic, clinical, and contextual factors may influence opportunities for participation. Although disparities in prostate cancer diagnosis and treatment are well documented, less is known about the factors associated with clinical research participation in this population. This study examined patient-level and contextual factors associated with clinical research participation among older Medicare beneficiaries with prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective claims-based analysis was conducted using the Medicare 5% Standard Analytical Files to identify men aged \u226565 years with a healthcare encounter for prostate cancer between January 1, 2016 and December 31, 2021. Clinical research participation was identified using the International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis code Z00.6 (\u201cEncounter for examination for normal comparison and control in clinical research program\u201d). Deidentified patient-level data were linked to 2020 county-level social determinants of health (SDOH) data from the Agency for Healthcare Research and Quality database. Multivariable logistic regression models were used to evaluate demographic, clinical, and county-level contextual factors associated with clinical research participation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 107,250 Medicare Fee-for-Service (FFS) beneficiaries with prostate cancer were identified, representing approximately 2.145 million FFS beneficiaries after standard extrapolation. Among this cohort, 4,361 (4.07%) beneficiaries had documented clinical research participation, corresponding to approximately 87,220 beneficiaries after extrapolation. Compared to beneficiaries without documented research participation, beneficiaries participating in clinical research were younger, more often White, had higher Charlson Comorbidity Index (CCI) scores, and higher rates of metastatic disease. Residence in counties with higher socioeconomic indicators, including higher median household income, lower unemployment, higher educational attainment, and greater internet access was also associated with clinical research participation. After controlling for age, race, and CCI score, adjusted analyses identified several patient-level clinical and geographic characteristics, as well as county-level contextual characteristics, associated with clinical research participation, including metastatic disease, census region, county-level median household income, and county-level median distance to the nearest emergency department.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings suggest that patient- and community-level factors may influence participation in clinical research. Targeted efforts to reduce structural and geographic barriers may help promote more equitable participation in clinical research among prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1887816","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:07:37Z","timestamp":1788426457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with clinical research participation among Medicare beneficiaries with prostate cancer in the United States"],"prefix":"10.3389","volume":"16","author":[{"given":"Ryan A.","family":"Hankins","sequence":"first","affiliation":[{"name":"Department of Urology, MedStar Georgetown University Hospital","place":["Washington, DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alysha M.","family":"McGovern","sequence":"additional","affiliation":[{"name":"Health Economics and Market Access, Boston Scientific","place":["Marlborough, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abimbola O.","family":"Williams","sequence":"additional","affiliation":[{"name":"Health Economics and Market Access, Boston Scientific","place":["Marlborough, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgil H.","family":"Simons","sequence":"additional","affiliation":[{"name":"The Prostate Net, Inc.","place":["Sanford, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[{"name":"University of South Florida (USF) Health Morsani College of Medicine","place":["Tampa, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[{"name":"Julius L. Chambers Biomedical\/Biotechnology Research Institute, Department of Pharmaceutical Sciences, North Carolina Central University","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"B2","unstructured":"Key statistics for prostate cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/op.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol Pr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0237","article-title":"Racial and ethnic composition of cancer clinical drug trials: How diverse are we","volume":"23","author":"Dickmann","year":"2018","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: An American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21638","article-title":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA: A Cancer J For Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.10162","article-title":"Social determinants of health and the availability of cancer clinical trials in the United States","volume":"7","author":"Sekar","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.04.076","article-title":"Participation of older patients with prostate cancer in Medicare eligible trials","volume":"184","author":"Craig","year":"2010","journal-title":"J Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5511","article-title":"Disparities in the inclusion of racial and ethnic minority groups and older adults in prostate cancer clinical trials","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.euros.2023.05.015","article-title":"A systematic review of patient race, ethnicity, socioeconomic status, and educational attainment in prostate cancer treatment randomised trials\u2014is the evidence base applicable to the general patient population","volume":"54","author":"Patki","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01030","article-title":"National estimates of the participation of patients with cancer in clinical research studies based on Commission on Cancer accreditation data","volume":"42","author":"Unger","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5020","article-title":"Clinical trial participation among older adult Medicare fee-for-service beneficiaries with cancer","volume":"8","author":"Green","year":"2022","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju002","article-title":"Comparison of survival outcomes among cancer patients treated in and out of clinical trials","volume":"106","author":"Unger","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2021.08.004","article-title":"Examining the racial disparities in prostate cancer","volume":"163","author":"Vince","year":"2022","journal-title":"Urology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_350751","article-title":"Health disparities in prostate cancer and approaches to advance equitable care","volume":"42","author":"Washington","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1186\/s13063-021-05849-7","article-title":"Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action","volume":"22","author":"Bodicoat","year":"2021","journal-title":"Trials"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106740","article-title":"Inclusion and diversity in clinical trials: Actionable steps to drive lasting change","volume":"116","author":"Kelsey","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmp2215609","article-title":"Why diverse clinical trial participation matters","volume":"388","author":"Schwartz","year":"2023","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28574","article-title":"Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: Enhancing minority participation in clinical trials (EMPaCT)","author":"Durant","year":"2014","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-016-0332-y","article-title":"Barriers and strategies for recruitment of racial and ethnic minorities: Perspectives from neurological clinical research coordinators","volume":"4","author":"Haley","year":"2017","journal-title":"J Racial Ethn Heal Disparities"},{"key":"B21","article-title":"Enhancing the diversity of clinical trial populations - eligiblity criteria, enrollment practices, and trial designs guidance for industry","year":"2020"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.e13682","article-title":"Assessing barriers to prostate cancer clinical trial participation among Black and African Americans: A multi-perspective qualitative study","volume":"42","author":"Leger","year":"2024","journal-title":"J Clin Oncol"},{"key":"B23","unstructured":"Chapter 32 - billing requirements for special services\n          \n          \n          Medicare Claims Processing Manual\n          \n          2026"},{"key":"B24","unstructured":"Social Determinants of Health Database"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1200\/op.2023.19.11_suppl.97","article-title":"Disparities in clinical trial participation beyond first-line treatment among patients with metastatic breast or colorectal cancer","volume":"19","author":"Wang","year":"2023","journal-title":"JCO Oncol Pr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-020-00119-z","article-title":"Metastatic hormone-sensitive prostate cancer (mHSPC): Advances and treatment strategies in the first-line setting","volume":"8","author":"Ng","year":"2020","journal-title":"Oncol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/rru.s385257","article-title":"Metastatic castration-resistant prostate cancer: Insights on current therapy and promising experimental drugs","volume":"15","author":"Ferretti","year":"2023","journal-title":"Res Rep Urol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.1","article-title":"Physician visits prior to treatment for clinically localized prostate cancer","volume":"170","author":"Jang","year":"2010","journal-title":"Arch Intern Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.05.013","article-title":"Examining exclusion criteria in advanced prostate cancer clinical trials: An assessment of recommendations from the American Society Of Clinical Oncology and Friends of Cancer Research","volume":"21","author":"Ebrahimi","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.2012.11286.x","article-title":"The effect of clinical trial participation versus non\u2010participation on overall survival in men receiving first\u2010line docetaxel\u2010containing chemotherapy for metastatic castration\u2010resistant prostate cancer","volume":"110","author":"Goyal","year":"2012","journal-title":"BJU Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/jco.2016.34.15_suppl.2534","article-title":"The effect of comorbidity on participation in early phase cancer trials","volume":"34","author":"Sheriff","year":"2016","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5953","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger","year":"2019","journal-title":"JAMA Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020485","article-title":"Motivation to clinical trial participation: Health information distrust and healthcare access as explanatory variables and gender as moderator","volume":"14","author":"Barsha","year":"2025","journal-title":"J Clin Med"},{"key":"B36","unstructured":"Diversity Action Plans to Improve Enrollment of Participants From Underrepresented Populations in Clinical Studies Draft: Guidance for Industry"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkab093","article-title":"Racial disparities in access to prostate cancer clinical trials: A county-level analysis","volume":"6","author":"Wang","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-868","article-title":"Winning hearts & minds: Prostate cancer outreach and clinical trial enrollment in minority men","volume":"13","author":"Anderson","year":"2024","journal-title":"Transl Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00427-z","article-title":"Drivers of racial disparities in prostate cancer trial enrollment","volume":"24","author":"Vince","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/aiu\/8871425","article-title":"Racial disparities in clinical trial enrollment among patients diagnosed with prostate cancer: A population\u2010based cohort of oncology practices","volume":"2024","author":"Wiesen","year":"2024","journal-title":"Adv Urol"},{"key":"B41","article-title":"Determining clinical perspectives and strategies for improving enrollment of minoritized communities in prostate cancer clinical trials","volume":"11","author":"Brady","year":"2023","journal-title":"Am J Clin Exp Urol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.09.029","article-title":"Minority recruitment trends in phase III prostate cancer clinical trials (2003-2014): Progress and critical areas for improvement","volume":"201","author":"Balakrishnan","year":"2018","journal-title":"J Urol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-19-1616","article-title":"Diversity of enrollment in prostate cancer clinical trials: Current status and future directions","volume":"29","author":"Rencsok","year":"2020","journal-title":"Cancer Epidemiol Prev biomark"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100066","article-title":"Dedicated research navigators: A tool to decrease disparities in clinical trial enrollment","volume":"35","author":"Boitano","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2023.06.002","article-title":"Selection and prejudice: Addressing clinical trial disparities with a review of current shortcomings and future directions","volume":"33","author":"Corrigan","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18865\/ed.32.1.61","article-title":"Advancing inclusive research: Establishing collaborative strategies to improve diversity in clinical trials","volume":"32","author":"Garrick","year":"2022","journal-title":"Ethn Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-019-01650-y","article-title":"Overcoming barriers: Evidence-based strategies to increase enrollment of underrepresented populations in cancer therapeutic clinical trials\u2014a narrative review","volume":"35","author":"Vuong","year":"2020","journal-title":"J Cancer Educ"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1887816\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:07:39Z","timestamp":1788426459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1887816\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":47,"alternative-id":["10.3389\/fonc.2026.1887816"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1887816","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1887816"}}